Lanoxin Related Published Studies
Well-designed clinical trials related to Lanoxin (Digoxin)
The hemodynamic and pharmacokinetic interactions between chronic use of oral levosimendan and digoxin in patients with NYHA Classes II-III heart failure. [2008.08]
No effect of imidafenacin, a novel antimuscarinic drug, on digoxin pharmacokinetics in healthy subjects. [2008]
Intravenous and oral administration of amiodarone for the treatment of recent onset atrial fibrillation after digoxin administration. [2007.10.18]
Digoxin bioequivalence study: determination in human plasma by microparticle enzyme immunoassay. [2007.06]
Digoxin and reduction in mortality and hospitalization in geriatric heart failure: importance of low doses and low serum concentrations. [2007.03]
Verapamil versus digoxin and acute versus routine serial cardioversion for the improvement of rhythm control for persistent atrial fibrillation. [2006.09.05]
Effects of digoxin on morbidity and mortality in diastolic heart failure: the ancillary digitalis investigation group trial. [2006.08.01]
Multiple doses of the antimuscarinic agent solifenacin do not affect the pharmacodynamics or pharmacokinetics of warfarin or the steady-state pharmacokinetics of digoxin in healthy subjects. [2006.08]
Predictive power of an in vitro system to assess drug interactions of an antimuscarinic medication: a comparison of in vitro and in vivo drug-drug interaction studies of trospium chloride with digoxin. [2006.07]
Serum digoxin concentration and outcomes in women with heart failure: A bi-directional effect and a possible effect modification by ejection fraction. [2006.06]
Digoxin and reduction in mortality and hospitalization in heart failure: a comprehensive post hoc analysis of the DIG trial. [2006.01]
Effect of milk thistle (Silybum marianum) and black cohosh (Cimicifuga racemosa) supplementation on digoxin pharmacokinetics in humans. [2006.01]
Influence of coadministration on the pharmacokinetics of azimilide dihydrochloride and digoxin. [2005.07]
No relevant interaction with alprazolam, caffeine, tolbutamide, and digoxin by treatment with a low-hyperforin St John's wort extract. [2005.04]
Cross-sectional study of heart failure therapy with angiotensin converting enzyme inhibitors and digoxin. [2004.08]
No pharmacokinetic or pharmacodynamic interaction between digoxin and the oral direct thrombin inhibitor ximelagatran in healthy volunteers. [2004.08]
Renal function, digoxin therapy, and heart failure outcomes: evidence from the digoxin intervention group trial. [2004.08]
Substantial pharmacokinetic interaction between digoxin and ritonavir in healthy volunteers. [2004.07]
Effect of St John's wort dose and preparations on the pharmacokinetics of digoxin. [2004.06]
Rapid loading of sotalol or amiodarone for management of recent onset symptomatic atrial fibrillation: a randomized, digoxin-controlled trial. [2004.01]
Comparative bioavailability study of two tablet formulations of digoxin. [2004]
Carvedilol alone or in combination with digoxin for the management of atrial fibrillation in patients with heart failure? [2003.12.03]
No clinically significant effect of erythromycin or azithromycin on the pharmacokinetics of voriconazole in healthy male volunteers. [2003.12]
Lack of effect of aprepitant on digoxin pharmacokinetics in healthy subjects. [2003.08]
Contribution of increased oral bioavailability and reduced nonglomerular renal clearance of digoxin to the digoxin-clarithromycin interaction. [2003.07]
Impact of ginkgo biloba on the pharmacokinetics of digoxin. [2003.07]
Interaction study between digoxin and a preparation of hawthorn (Crataegus oxyacantha). [2003.06]
[Clinical study on effect of shengmai injection on serum concentration and pharmacokinetic parameters of digoxin in patients with congestive heart failure] [2003.05]
Pharmacokinetic and pharmaceutic interaction between digoxin and Cremophor RH40. [2003.05]
Hypothalamic digoxin-mediated model for Parkinson's disease. [2003.04]
Intravenously administered digoxin in patients with acute atrial fibrillation: a population pharmacokinetic/pharmacodynamic analysis based on the Digitalis in Acute Atrial Fibrillation trial. [2003.03]
Association of serum digoxin concentration and outcomes in patients with heart failure. [2003.02.19]
The effect of digoxin on the quality of life in patients with heart failure. [2003.02]
Teriparatide has no effect on the calcium-mediated pharmacodynamics of digoxin. [2003.01]
Dipyridamole enhances digoxin bioavailability via P-glycoprotein inhibition. [2003.01]
No effect of rosuvastatin on the pharmacokinetics of digoxin in healthy volunteers. [2002.12]
Sex-based differences in the effect of digoxin for the treatment of heart failure. [2002.10.31]
Do therapeutic doses of acarbose alter the pharmacokinetics of digoxin? [2002.10]
The effect of erythromycin and clarithromycin on the pharmacokinetics of intravenous digoxin in healthy volunteers. [2002.10]
Investigation of the interaction between argatroban and acetaminophen, lidocaine, or digoxin. [2002.07.01]
Double-blind placebo-controlled trial of aprindine and digoxin for the prevention of symptomatic atrial fibrillation. [2002.06]
A comparison between the effects of diltiazem and isosorbide dinitrate on digoxin pharmacodynamics and kinetics in the treatment of patients with chronic ischemic heart failure. [2002.06]
Clinical benefits of low serum digoxin concentrations in heart failure. [2002.03.20]
Amiodarone versus digoxin and metoprolol combination for the prevention of postcoronary bypass atrial fibrillation. [2002.03]
Absence of a pharmacokinetic interaction between digoxin and levofloxacin. [2002.02]
Absence of interaction of fondaparinux sodium with digoxin in healthy volunteers. [2002]
Effect of grapefruit juice on digoxin pharmacokinetics in humans. [2001.10]
The effects of tegaserod (HTF 919) on the pharmacokinetics and pharmacodynamics of digoxin in healthy subjects. [2001.10]
Effect of age on mortality, hospitalizations and response to digoxin in patients with heart failure: the DIG study. [2001.09]
Repeated administration of the novel antiepileptic agent levetiracetam does not alter digoxin pharmacokinetics and pharmacodynamics in healthy volunteers. [2001.08]
VERDICT: the Verapamil versus Digoxin Cardioversion Trial: A randomized study on the role of calcium lowering for maintenance of sinus rhythm after cardioversion of persistent atrial fibrillation. [2001.07]
Cilomilast: pharmacokinetic and pharmacodynamic interactions with digoxin. [2001.06]
Comparison of digoxin versus low-dose amiodarone for ventricular rate control in patients with chronic atrial fibrillation. [2001.05]
Digoxin to facilitate late second-trimester abortion: a randomized, masked, placebo-controlled trial. [2001.03]
Sevelamer hydrochloride (Renagel), a nonabsorbed phosphate-binding polymer, does not interfere with digoxin or warfarin pharmacokinetics. [2001.02]
Acute ventricular rate control in atrial fibrillation: IV combination of diltiazem and digoxin vs. IV diltiazem alone. [2001.02]
Effect of dofetillide on the pharmacokinetics of digoxin. [2001.01.15]
Effect of rofecoxib on the pharmacokinetics of digoxin in healthy volunteers. [2001.01]
Rosiglitazone does not affect the steady-state pharmacokinetics of digoxin. [2000.12]
The effect of telmisartan on the steady-state pharmacokinetics of digoxin in healthy male volunteers. [2000.12]
Study on the interaction of the dopamine agonist alpha-dihydroergocryptine with the pharmacokinetics of digoxin. [2000.07]
Oral bioavailability of digoxin is enhanced by talinolol: evidence for involvement of intestinal P-glycoprotein. [2000.07]
A prospective, randomized controlled trial comparing the efficacy and safety of sotalol, amiodarone, and digoxin for the reversion of new-onset atrial fibrillation. [2000.07]
Effect of digoxin on global respiratory muscle strength after cholecystectomy: a double blind study. [2000.06]
Effect of digoxin on circadian blood pressure values in patients with congestive heart failure. [2000.04]
The effects of exercise training on the pharmacokinetics of digoxin. [2000.03]
[Systematic review of the effectiveness and indications of antidigoxin antibodies in the treatment of digitalis intoxication] [2000.01]
Natural surfactant extract versus synthetic surfactant for neonatal respiratory distress syndrome. [2000]
Evaluation of phototoxic potential of gemifloxacin in healthy volunteers compared with ciprofloxacin. [1999.11]
Digoxin: use pattern in Estonia and bioavailability of the local market leader. [1999.10]
Pharmacokinetic and pharmacodynamic drug interactions between digoxin and macrogol 4000, a laxative polymer, in healthy volunteers. [1999.09]
Effect of multiple doses of montelukast, a CysLT1 receptor antagonist, on digoxin pharmacokinetics in healthy volunteers. [1999.09]
Double-blind placebo-controlled trial of digoxin in symptomatic paroxysmal atrial fibrillation. [1999.06.01]
The local effects of systemic digoxin on the cutaneous microcirculation. [1999.06]
The effect of bosentan on the pharmacokinetics of digoxin in healthy male subjects. [1999.06]
Pharmacokinetic interaction of sparfloxacin and digoxin. [1999.02]
The effect of steady-state ropinirole on plasma concentrations of digoxin in patients with Parkinson's disease. [1999.02]
Effects of digoxin on electrocardiogram in patients with acute atrial fibrillation--a randomized, placebo-controlled study. Digitalis in Acute Atrial Fibrillation (DAAF) Trial Group. [1999.02]
The effect of multiple doses of donepezil HCl on the pharmacokinetic and pharmacodynamic profile of warfarin. [1998.11]
Comparison between propafenone and digoxin administered intravenously to patients with acute atrial fibrillation. PAFIT-3 Investigators. The Propafenone in Atrial Fibrillation Italian Trial. [1998.09.01]
Effects of digoxin and digitoxin on circadian blood pressure profile in healthy volunteers. [1998.09]
Mid- and long-term similarity of ventricular response to paroxysmal atrial fibrillation: digoxin versus placebo. [1998.09]
Superiority of "triple" drug therapy in heart failure: insights from the PROVED and RADIANCE trials. Prospective Randomized Study of Ventricular Function and Efficacy of Digoxin. Randomized Assessment of Digoxin and Inhibitors of Angiotensin-Converting Enzyme. [1998.09]
Impairment of absorption of digoxin by acarbose. [1998.07]
Tiagabine, a novel antiepileptic agent: lack of pharmacokinetic interaction with digoxin. [1998.06]
A randomized, double-blind comparison of intravenous diltiazem and digoxin for atrial fibrillation after coronary artery bypass surgery. [1998.05]
[Comparison of the effects of digoxin or enalapril in the treatment of heart failure due to mitral insufficiency] [1998.03]
Lack of interaction between valaciclovir, the L-valyl ester of aciclovir, and digoxin. [1998.01]
[Digoxin: continuous or discontinuous treatment?] [1998]
Itraconazole decreases renal clearance of digoxin. [1997.12]
Effects of terbinafine on the pharmacokinetics of digoxin in healthy volunteers. [1997.07]
Lack of effect of eprosartan on the single dose pharmacokinetics of orally administered digoxin in healthy male volunteers. [1997.06]
Digoxin therapy in chronic heart failure. [1997.05]
Pharmacokinetic and pharmacodynamic interaction trial after repeated oral doses of imidapril and digoxin in healthy volunteers. [1997.05]
Effects of diltiazem versus digoxin on dysrhythmias and cardiac function after pneumonectomy. [1997.05]
Conversion of atrial fibrillation to sinus rhythm and rate control by digoxin in comparison to placebo. [1997.04]
Emergency management of atrial fibrillation and flutter: intravenous diltiazem versus intravenous digoxin. [1997.01]
Effectiveness of verapamil-quinidine versus digoxin-quinidine in the emergency department treatment of paroxysmal atrial fibrillation. [1997.01]
Effect of digoxin on the ventricular rate variability during paroxysmal atrial fibrillation. [1996.11]
Itraconazole increases serum digoxin concentration. [1996.11]
Rationale and design of the third vasodilator-heart failure trial (V-HeFT III): felodipine as adjunctive therapy to enalapril and loop diuretics with or without digoxin in chronic congestive heart failure. V-HeFT III investigators. [1996.05.15]
|
